利用纤维细胞生长因子受体-1的脆弱性,以治疗性地限制MYC-EZH2-CDKN1C轴驱动的扩散在地幔细胞淋巴瘤中
Anuvrat Sircar1,2, Satishkumar Singh1,2, Zijun Y Xu-Monette3
1Division of Hematology, College of Medicine, The Ohio State University, Columbus, OH, USA.
Leukemia
|August 19, 2023
概括
膜细胞淋巴瘤 (MCL) 细胞依赖纤维细胞生长因子受体-1 (FGFR1) 进行增殖. 用herdafitinib准FGFR1在治疗这种致命癌症方面显示出有前途.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 膜细胞淋巴瘤 (MCL) 是一种具有不良预后的侵袭性血液性恶性瘤.
- 瘤进展和MCL中药物耐药性尚不清楚,因此需要新的治疗点.
- 瘤微环境 (TME) 有助于MCL的亲瘤性和耐药性.
研究的目的:
- 为了确定质细胞淋巴瘤 (MCL) 药物治疗的新分子标.
- 研究纤维细胞生长因子受体-1 (FGFR1) 在MCL进展中的作用.
- 在临床前的MCL模型中评估向FGFR1的治疗潜力.
主要方法:
- 对MCL患者样本的综合转录基因分析.
- 功能研究包括药理干预和功能丧失实验.
- 在临床前评估FGFR抑制剂herdafitinib,在体外和体外MCL模型.
主要成果:
- 在MCL患者中高FGFR1表达与较短的整体存活率相关.
- 一个新的MYC-EZH2-CDKN1C轴驱动着MCL的扩散.
- 埃尔达菲提尼布治疗诱导了细胞循环停止,细胞死亡,抑制了瘤进展,并在临床前模型中改善了生存率.
结论:
- 质细胞淋巴瘤 (MCL) 中,FGFR1 是一个可行的治疗点.
- 针对FGFR1-MYC-EZH2-CDKN1C轴与erdafitinib的向显示了MCL的显著治疗潜力.
- 需要对ERDAFITINIB进行进一步的临床研究,以治疗MCL.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Induced Pluripotent Stem Cells
4.2K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


